Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination

被引：27

作者：

Basyte-Bacevice, Viktorija ^{[1
]}

Kupcinskas, Juozas ^{[1
,2
]}

机构：

[1] Lithuanian Univ Hlth Sci, Dept Gastroenterol, Eiveniu St 2, LT-50009 Kaunas, Lithuania

[2] Lithuanian Univ Hlth Sci, Inst Digest Res, Eiveniu St 2, LT-50009 Kaunas, Lithuania

来源：

DIGESTIVE DISEASES | 2020年 / 38卷 / 02期

关键词：

Hepatitis C virus; Hepatology; Liver; RECOMBINANT INTERFERON-ALPHA; TREATMENT-NAIVE PATIENTS; VIRUS GENOTYPE 1; VIRAL-HEPATITIS; DOUBLE-BLIND; POSTTRANSFUSION HEPATITIS; COMBINATION TREATMENT; PEGYLATED INTERFERON; INITIAL TREATMENT; CHRONIC INFECTION;

D O I：

10.1159/000505434

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Discovery of hepatitis C in 1989 allowed basic research to identify critical components of hepatitis C virus (HCV) structure and life cycle. Interferon (IFN)-alpha was introduced as first treatment for chronic hepatitis C and later was enhanced by pegylation, addition of ribavirin, and resulted in improved sustained virologic response. Better understanding of HCV structure, enzymes, and lifecycle led to the discovery of direct-acting antivirals and IFN-free era. Successful HCV therapy created a rare possibility of global disease eradication, which is now a major goal internationally. However, hepatitis C remains a major public health challenge, and more resources are needed to reach global elimination.

引用

页码：137 / 142

页数：6

共 64 条

[31] MOLECULAR-CLONING OF THE HUMAN HEPATITIS-C VIRUS GENOME FROM JAPANESE PATIENTS WITH NON-A, NON-B HEPATITIS [J].

KATO, N ;

HIJIKATA, M ;

OOTSUYAMA, Y ;

NAKAGAWA, M ;

OHKOSHI, S ;

SUGIMURA, T ;

SHIMOTOHNO, K .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (24) :9524-9528

[32] Clinically immune hosts as a refuge for drug-sensitive malaria parasites [J].

Klein, Eili Y. ;

Smith, David L. ;

Boni, Maciej F. ;

Laxminarayan, Ramanan .

MALARIA JOURNAL, 2008, 7 (1)

[33] Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis [J].

Kowdley, Kris V. ;

Gordon, Stuart C. ;

Reddy, K. Rajender ;

Rossaro, Lorenzo ;

Bernstein, David E. ;

Lawitz, Eric ;

Shiffman, Mitchell L. ;

Schiff, Eugene ;

Ghalib, Reem ;

Ryan, Michael ;

Rustgi, Vinod ;

Chojkier, Mario ;

Herring, Robert ;

Di Bisceglie, Adrian M. ;

Pockros, Paul J. ;

Subramanian, G. Mani ;

An, Di ;

Svarovskaia, Evguenia ;

Hyland, Robert H. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Pound, David ;

Fried, Michael W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1879-1888

[34] VIRAL HEPATITIS - NEW LIGHT ON AN OLD DISEASE [J].

KRUGMAN, S ;

GILES, JP .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1970, 212 (06) :1019-&

[35] INFECTIOUS HEPATITIS [J].

KRUGMAN, S ;

GILES, JP ;

HAMMOND, J .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1967, 200 (05) :365-+

[36] Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study [J].

Lawitz, Eric ;

Sulkowski, Mark S. ;

Ghalib, Reem ;

Rodriguez-Torres, Maribel ;

Younossi, Zobair M. ;

Corregidor, Ana ;

DeJesus, Edwin ;

Pearlman, Brian ;

Rabinovitz, Mordechai ;

Gitlin, Norman ;

Lim, Joseph K. ;

Pockros, Paul J. ;

Scott, John D. ;

Fevery, Bart ;

Lambrecht, Tom ;

Ouwerkerk-Mahadevan, Sivi ;

Callewaert, Katleen ;

Symonds, William T. ;

Picchio, Gaston ;

Lindsay, Karen L. ;

Beumont, Maria ;

Jacobson, Ira M. .

LANCET, 2014, 384 (9956) :1756-1765

[37] A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C [J].

Lindsay, KL ;

Trepo, C ;

Heintges, T ;

Shiffman, ML ;

Gordon, SC ;

Hoefs, JC ;

Schiff, ER ;

Goodman, ZD ;

Laughlin, M ;

Yao, RJ ;

Albrecht, JK .

HEPATOLOGY, 2001, 34 (02) :395-403

[38] Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Manns, Michael ;

Marcellin, Patrick ;

Poordad, Fred ;

Affonso de Araujo, Evaldo Stanislau ;

Buti, Maria ;

Horsmans, Yves ;

Janczewska, Ewa ;

Villamil, Federico ;

Scott, Jane ;

Peeters, Monika ;

Lenz, Oliver ;

Ouwerkerk-Mahadevan, Sivi ;

De La Rosa, Guy ;

Kalmeijer, Ronald ;

Sinha, Rekha ;

Beumont-Mauviel, Maria .

LANCET, 2014, 384 (9941) :414-426

[39] Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].

McHutchison, JG ;

Gordon, SC ;

Schiff, ER ;

Shiffman, ML ;

Lee, WM ;

Rustgi, VK ;

Goodman, ZD ;

Ling, MH ;

Cort, S ;

Albrecht, JK .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492

[40] The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors [J].

Membreno, Fernando E. ;

Lawitz, Eric J. .

CLINICS IN LIVER DISEASE, 2011, 15 (03) :611-+

← 1 2 3 4 5 6 7 →